Cargando…

Ethanol and C2 ceramide activate fatty acid oxidation in human hepatoma cells

Obesogenic lipids and the sphingolipid ceramide have been implicated as potential cofactors in alcoholic liver disease (ALD) patients. However, the mechanisms by which these lipids modulate lipid trafficking in ethanol-treated human liver cells to promote steatosis, an early stage of ALD, are poorly...

Descripción completa

Detalles Bibliográficos
Autores principales: Correnti, Jason M., Gottshall, Lauren, Lin, Annie, Williams, Bianca, Oranu, Amanke, Beck, James, Chen, Jie, Bennett, Michael J., Carr, Rotonya M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110824/
https://www.ncbi.nlm.nih.gov/pubmed/30150688
http://dx.doi.org/10.1038/s41598-018-31025-0
_version_ 1783350545492213760
author Correnti, Jason M.
Gottshall, Lauren
Lin, Annie
Williams, Bianca
Oranu, Amanke
Beck, James
Chen, Jie
Bennett, Michael J.
Carr, Rotonya M.
author_facet Correnti, Jason M.
Gottshall, Lauren
Lin, Annie
Williams, Bianca
Oranu, Amanke
Beck, James
Chen, Jie
Bennett, Michael J.
Carr, Rotonya M.
author_sort Correnti, Jason M.
collection PubMed
description Obesogenic lipids and the sphingolipid ceramide have been implicated as potential cofactors in alcoholic liver disease (ALD) patients. However, the mechanisms by which these lipids modulate lipid trafficking in ethanol-treated human liver cells to promote steatosis, an early stage of ALD, are poorly understood. We measured fatty acid (FA) uptake, triglyceride export, FA synthesis and FA oxidation in human hepatoma (VL-17A) cells in response to ethanol and the exogenous lipids oleate, palmitate and C2 ceramide. We found that in combination with ethanol, both oleate and palmitate promote lipid droplet accumulation while C2 ceramide inhibits lipid droplet accumulation by enhancing FA oxidation. Further, using both a pharmacologic and siRNA approach to reduce peroxisome proliferator-activated receptors α (PPARα) gene expression, we demonstrate that C2 ceramide abrogates ethanol-mediated suppression of FA oxidation through an indirect PPARα mechanism. Together, these data suggest that lipids interact differentially with ethanol to modulate hepatocellular lipid droplet accumulation and may provide novel targets for preventing the earliest stage of alcoholic liver disease, alcoholic steatosis.
format Online
Article
Text
id pubmed-6110824
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61108242018-08-30 Ethanol and C2 ceramide activate fatty acid oxidation in human hepatoma cells Correnti, Jason M. Gottshall, Lauren Lin, Annie Williams, Bianca Oranu, Amanke Beck, James Chen, Jie Bennett, Michael J. Carr, Rotonya M. Sci Rep Article Obesogenic lipids and the sphingolipid ceramide have been implicated as potential cofactors in alcoholic liver disease (ALD) patients. However, the mechanisms by which these lipids modulate lipid trafficking in ethanol-treated human liver cells to promote steatosis, an early stage of ALD, are poorly understood. We measured fatty acid (FA) uptake, triglyceride export, FA synthesis and FA oxidation in human hepatoma (VL-17A) cells in response to ethanol and the exogenous lipids oleate, palmitate and C2 ceramide. We found that in combination with ethanol, both oleate and palmitate promote lipid droplet accumulation while C2 ceramide inhibits lipid droplet accumulation by enhancing FA oxidation. Further, using both a pharmacologic and siRNA approach to reduce peroxisome proliferator-activated receptors α (PPARα) gene expression, we demonstrate that C2 ceramide abrogates ethanol-mediated suppression of FA oxidation through an indirect PPARα mechanism. Together, these data suggest that lipids interact differentially with ethanol to modulate hepatocellular lipid droplet accumulation and may provide novel targets for preventing the earliest stage of alcoholic liver disease, alcoholic steatosis. Nature Publishing Group UK 2018-08-27 /pmc/articles/PMC6110824/ /pubmed/30150688 http://dx.doi.org/10.1038/s41598-018-31025-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Correnti, Jason M.
Gottshall, Lauren
Lin, Annie
Williams, Bianca
Oranu, Amanke
Beck, James
Chen, Jie
Bennett, Michael J.
Carr, Rotonya M.
Ethanol and C2 ceramide activate fatty acid oxidation in human hepatoma cells
title Ethanol and C2 ceramide activate fatty acid oxidation in human hepatoma cells
title_full Ethanol and C2 ceramide activate fatty acid oxidation in human hepatoma cells
title_fullStr Ethanol and C2 ceramide activate fatty acid oxidation in human hepatoma cells
title_full_unstemmed Ethanol and C2 ceramide activate fatty acid oxidation in human hepatoma cells
title_short Ethanol and C2 ceramide activate fatty acid oxidation in human hepatoma cells
title_sort ethanol and c2 ceramide activate fatty acid oxidation in human hepatoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110824/
https://www.ncbi.nlm.nih.gov/pubmed/30150688
http://dx.doi.org/10.1038/s41598-018-31025-0
work_keys_str_mv AT correntijasonm ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells
AT gottshalllauren ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells
AT linannie ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells
AT williamsbianca ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells
AT oranuamanke ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells
AT beckjames ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells
AT chenjie ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells
AT bennettmichaelj ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells
AT carrrotonyam ethanolandc2ceramideactivatefattyacidoxidationinhumanhepatomacells